PSMA Binding Agent Diagnostic Kit for Prostate Cancer Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for prostate cancer are limited, especially for metastasized cases, with systemic therapies offering only palliative benefits and significant side effects, and there is a need for more effective and less toxic treatments that can predict patient response to therapy.
Innovation Solution
The development of methods and kits that use detectably labeled binding agents to identify patients suitable for cancer therapy by binding to specific molecular targets, such as Prostate Specific Membrane Antigen (PSMA), allowing for non-invasive diagnosis and selection of patients for targeted therapies, thereby improving treatment efficacy and reducing unnecessary exposure to toxic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic therapy (androgen deprivation) is used for metastasized prostate cancer, then initial clinical improvement is achieved, but androgen-independent cells develop and therapy becomes palliative not curative
Solution Approach 1:
The patent applies preliminary action by using a diagnostic binding agent to identify patients who are likely to respond to therapeutic binding agents before treatment is administered. This pre-screening approach ensures that only patients with suitable molecular targets receive the full therapeutic regimen, thereby preventing the development of androgen-independent cells and extending the duration of therapeutic response.
Solution Approach 2:
The patent employs parameter changes by transitioning from non-specific systemic therapy to targeted therapy based on molecular marker expression levels. By measuring and responding to specific biomarker parameters (PSMA expression levels), the treatment approach is adapted to individual patient characteristics, improving both reliability and duration of therapeutic effectiveness.
2Reliability
If radical prostatectomy is performed on patients with localized cancer, then disease eradication is achieved, but many cancers have already spread beyond surgical boundaries by detection time
Solution Approach 1:
The patent applies preliminary action through early detection using PSA testing and diagnostic binding agents that identify molecular targets before cancer spreads. This allows intervention at an earlier stage when the disease is still localized and curable, reducing the loss of time between cancer onset and effective treatment.
3Adaptability or versatility
If radiation therapy is used for prostate cancer treatment, then alternative treatment option is provided, but PSA concentrations often increase again within two years signaling disease recurrence
Solution Approach 1:
The patent employs parameter changes by using diagnostic binding agents to identify specific molecular targets (PSMA expression levels) that predict response to radiation therapy. This allows selection of patients most likely to achieve long-term remission from radiation, extending the duration of therapeutic action for those who respond.
4Reliability
If toxic therapeutic agents are administered to all prostate cancer patients, then treatment coverage is maximized, but unnecessary exposure to side effects occurs in non-responders
Solution Approach 1:
The patent applies local quality by using diagnostic binding agents to identify specific molecular targets in individual patients. This enables tailored treatment where toxic therapeutic agents are administered only to patients whose tumors express the relevant molecular targets, providing localized precision therapy that maximizes effectiveness while minimizing unnecessary side effects in non-responders.
Solution Approach 2:
The patent employs self-service through the use of detectably labeled binding agents that automatically identify patients who will respond to therapy based on their own molecular target expression. The diagnostic process is self-directed, requiring minimal external intervention to determine which patients should receive toxic therapeutic agents, thereby reducing unnecessary exposure while maintaining comprehensive treatment coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of patients likely to benefit from specific therapies, sparing those who won't respond and potentially reducing treatment side effects, while also improving the statistical significance of clinical trials by selecting the most responsive patients.
Implementation Method 1
administering a diagnostic dose of a detectably labeled first binding agent to a patient. The detectably labeled first binding agent is capable of binding a molecular target
Data Source
AI summary
A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.